Newsroom
Here is a listing of our current media-related activities and resources along with links to our archive:
Articles and Press Coverage
| The Atlantic, "Will Patients Bear the Burden for Developing Their Own Treatments?," May 10, 2012. |
| The Atlantic, "Mission Critical: How Disease-Specific Foundations May Save Medical Research," April 20, 2012. |
| San Francisco Business Times, "One-on-One with UCSF researcher Jonah Chan," April 19, 2012. |
| Huffington Post, "Hilary Rosen Should Donate to Multiple Sclerosis Foundations," April 12, 2012. |
| Silicon Valley/San Jose Business Journal, "Clinical trial to target multiple sclerosis," March 7, 2012. |
| Xconomy, "Disease foundations play growing role in biotech business model," March 6, 2012. |
| USA Today, "Parents of twins with rare disease fight for FDA approval of treatment," March 6, 2012. |
| Drug Discovery News, "Engendering the collaborative spirit to cure MS," March 2012. |
| Clinical trial examines Myelin Toleraization of the Immune System — Drug Discovery & Development Magazine. (3-8-12) |
| Partnering for a Cure: Stanford Social Innovation Review features Ideas/First Person column by Scott Johnson. (10-25-11) |
| California Health Institute blog posts Q&A with Scott Johnson about his personal mission to push the boundaries of biomedical collaboration. (5-5-11) |
| NY Times columnist David Bornstein: "Serving as a kind of switchboard, where people from different disciplines and sectors converge, M.R.F. can recognize opportunities that might otherwise go unnoticed." Read more about how the Myelin Repair Foundation is crossing boundaries to accelerate research. (5-5-11) |
| NY Times columnist David Bornstein: "The explosion in biomedical sciences has made it virtually impossible for industry researchers to keep up." Read more about how the Myelin Repair Foundation is part of the solution. (5-2-11) |
| Fast Company (3-1-11): Myelin Repair Foundation Named Among Top 10 Biotechs. |
| Fast Company (2-4-11): Online Game Crowdsources Ideas to Accelerate Medical Research |
| The Scientist features the Myelin Repair Foundation in an article that examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries. Read more: The Profits of Nonprofit. (January 1, 2011) |
| Myelin Repair Foundation-hosted Breakthroughs to Cures named #7 among top 10 social impact games of 2010. (December 31, 2010) |
| Myelin Repair Group Works to Develop Drugs, Cure MS (December 27, 2010) |
| Fast Company — Nov. 1, 2010 – “The Myelin Repair Foundation Encourages Collaboration for a Cure” |
| Kauffman Foundation Translational Medicine Alliance 2010 Forum, Washington, DC. October 13-14. Scott Johnson spoke on the panel, “Rethinking Everything: If we were starting over, what would we do differently” with Jonathan Jacoby from The R.A.R.E. Project and Lt Col Daniel J. Wattendorf, MD from DARPA. |
| UC Davis Alumni Magazine – Fall 2010 – Spotlight’s Scott Johnson’s work with the Myelin Repair Foundation |
| E-Week — “Online Gaming Event Seeks to Spur Search for Cures to Intractable Diseases” (Sep. 30, 2010) |
| Huffington Post — Julia Moulden covers Breakthroughs to Cures – Sep. 25, 2010 |
| PBS Newshour — Sep. 23, 2010 – “For Scientists, Collaborative Efforts Could Speed Medical Advances” |
| FierceBiotech Research — Sep. 14, 2010 – “Foundation uses gaming to inspire rad R&D thinking” |
| Smart Business Northern California — July 2010 – “Engaging the Chain” |
| Newsweek — May 10, 2010 – “Desperately Seeking Cures” Mary Carmichael and Sharon Begley discuss how the road from promising scientific breakthrough to real-world remedy has become all but a dead end. The Myelin Repair Foundation is mentioned as a model for fixing the system. |
| Kansas City Business Journal — March 26, 2010 – “Ewing Marion Kauffman Foundation Continues Push For Commercializing Drugs” |
| Silicon Valley/San Jose Business Journal — October 16, 2009 – Foundation’s research model in Saratoga aims to halve clinical trial time. |
| Forbes Magazine — July 13, 2009 – What Brain Researchers Forgot Kerry Dolan discusses a recent discovery by one of our Principal Investigators, Ben Barres, on the role of glial cells. Because of the unique functions that these cells perform in the brain, Myelin Repair Foundation scientists hope to exploit their therapeutic potential in further studies. |
| KansasCity.com — May 11, 2009 – Company turns research process on its head. |
| Elizabeth Edersheim Blog — April 2009 – Working Together to Heal |
| America.gov — December 2008 – Foundation Tests Entrepreneurial Model for Medical Research |
| Newsweek On Science — November 2008 – Where are the Cures? Scientists Call the Gulf between Biomedical Discovery and New Treatment the ‘Valley of Death’ |
| MS Focus Magazine — Summer 2008 – Paths to Progress features Myelin Repair Foundation update on myelin repair research. |
| biotechTransfer week — June 4, 2008 – Myelin Repair Foundation Taps CDD Software to Support ‘Accelerated’ Academic Research |
| BusinessWeek — May 7, 2008 – John Hagel and John Seely Brown review Myelin Repair Foundation’s ARC model in Innovation on the Edge. |
| San Francisco Chronicle — March 29, 2008 – Non-Profit Gears Up for Biotech Roadshow |
| The New Yorker— January 28, 2008 – Buying a Cure |
| Wall Street Journal – December 6, 2007 – Big Pharma Faces Grim Prognosis Barbara Martinez and Jacob Goldstein write about the challenges facing the pharmaceutical industry as a result of top-selling drugs going off-patent along with the poor outlook for new blockbusters. |
| View entire articles and press coverage archive. |
- Back to top -
Related News Articles
| The Economist – December 10, 2009 – Back to the lab Roche CEO Severin Schwan acknowledges today’s challenges for the pharmaceutical industry: “Drugmaking is ‘so crude’, Schwan argues, that half of all known diseases cannot be treated at all, and the drugs for the other half work properly only half the time and with huge side effects. ‘Imagine a car that starts only half the time, and whose brakes often don’t work,’ he says.” |
| Forbes- July 13, 2009 – What Brain Researchers Forgot. Forbes Magazine’s Kerry Dolan discusses a recent discovery by one of our Principal Investigators, Ben Barres, on the role of glial cells. Glial cells include oligodendrocytes (responsible for myelination) and astrocytes (the subject of the report), which represents the group of cells in the brain that is studied by Myelin Repair Foundation scientists. As the article points out, glial cells constitute 90% of the cells in the brain and are involved in promoting important neural functions. The article suggests the manipulation of glial cells as an innovative approach to treating neurodegenerative disorders. Because of the unique functions that these cells perform in the brain, Myelin Repair Foundation scientists hope to exploit their therapeutic potential in further studies. Read and share today! |
| The New York Times – June 27, 2009 – Grant System Leads Cancer Researchers to Play It Safe New York Times reporter, Gina Kolata, sheds light on flaws in traditional medical research funding. Read and share today! |
| Newsweek – June 15, 2009 – From Bench to Bedside: Academia slows the search for cures. Newsweek’s Sharon Begley takes the NIH to task for not meeting its commitment to translational research and encourages President Obama to appoint an NIH director who can make bench to bedside a reality. Share it with all who care about speeding cures to patients |
- Back to top -
Press Releases
- Back to top -
Research Reports
| Summary of Game Results Details and ideas that resulted from the first-of-a-kind crowd sourcing project. |
| Myelin Repair Research Highlights (2009) |
| Annual Review of Research Progress 2006 – 2007 (PDF) |
| Winter 2007 – Myelin Repair Foundation Research Progress Update (PDF) |
| View entire research reports archive. |
- Back to top -
Whitepapers
| Accelerated Research Collaboration™ (ARC™) (PDF) |
| Research Plan Summary (PDF) |
| Comments from Myelin Repair Foundation participants (PDF) |
| Background Whitepaper (PDF) |
| Background Summary (PDF) December 2003 |
| View entire whitepaper archive. |
- Back to top -
Your Donation Matters
Our work is made possible by the generous donations of individuals, foundations and corporations who believe in the promise of myelin repair and share our commitment to deliver a new treatment to MS patients as fast as possible.
Please help us maintain our momentum. Your gift today will help us reach the first myelin repair Phase I Clinical Trial by 2014.
Making Connections for a Cure
Learn More: Find out what makes us different. Watch Making Connections for a Cure.
Download our accompanying brochure and share with friends.
Stay Up To Date on MRF’s News and Research
Sign up to receive our FREE newsletter, MyelinConnection, via email.
